The introduction of smart insulin pens, which represent a substantial development in the technology currently used to control diabetes, may benefit patients who are reliant on insulin by enhancing ...
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
With an attractive sub-$500 starting price tag, for a split second, I wondered whether I'd be better off with a Chromebook — but one dealbreaker slapped me right back into reality. Still ...